Secondaries announced 12.17.2015

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating.

Company: Iradimed Corporation
Symbol: IRMD
Price: Last trade $24.68
Trade Date: 12/18
Shares: TBD
Underwriter(s) Roth Capital Partners
Rating=Subscription Needed